STOCK TITAN

CENTENE ANNOUNCES THE ELECTION OF THOMAS GRECO TO BOARD OF DIRECTORS

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Centene (NYSE: CNC) has appointed Thomas R. Greco to its Board of Directors, effective Aug. 9, 2024. This expands the board to 11 members, with Greco's term running through the 2025 annual meeting. Greco, a seasoned executive with over 40 years of public company leadership, most recently served as President and CEO of Advance Auto Parts from 2016 to 2023. Prior to that, he spent three decades at PepsiCo, eventually becoming CEO of Frito-Lay North America in 2011.

Centene CEO Sarah M. London highlighted Greco's expertise in consumer marketing as valuable for transforming the health of 28.5 million Americans. Greco currently serves on the boards of Tapestry, Inc., Sabra Dipping Company , and the American Heart Association. He expressed enthusiasm for Centene's commitment to helping members live healthier lives.

Centene (NYSE: CNC) ha nominato Thomas R. Greco nel suo Consiglio di Amministrazione, con effetto dal 9 agosto 2024. Questo ampliamento porta il consiglio a 11 membri, con il mandato di Greco che durerà fino all'assemblea annuale del 2025. Greco, un dirigente esperto con oltre 40 anni di leadership in aziende pubbliche, ha recentemente ricoperto il ruolo di Presidente e CEO di Advance Auto Parts dal 2016 al 2023. In precedenza, ha trascorso tre decenni in PepsiCo, diventando infine CEO di Frito-Lay North America nel 2011.

Il CEO di Centene, Sarah M. London, ha sottolineato l'expertise di Greco nel marketing dei consumatori come preziosa per trasformare la salute di 28,5 milioni di americani. Attualmente, Greco fa parte dei consigli di amministrazione di Tapestry, Inc., Sabra Dipping Company e della American Heart Association. Ha espresso entusiasmo per l'impegno di Centene nell'aiutare i membri a vivere vite più sane.

Centene (NYSE: CNC) ha nombrado a Thomas R. Greco en su Junta Directiva, a partir del 9 de agosto de 2024. Esto expande la junta a 11 miembros, con el mandato de Greco que se extenderá hasta la reunión anual de 2025. Greco, un ejecutivo experimentado con más de 40 años de liderazgo en empresas públicas, se desempeñó más recientemente como Presidente y CEO de Advance Auto Parts desde 2016 hasta 2023. Antes de eso, pasó tres décadas en PepsiCo, y finalmente se convirtió en CEO de Frito-Lay North America en 2011.

La CEO de Centene, Sarah M. London, destacó la experiencia de Greco en marketing de consumidores como valiosa para transformar la salud de 28.5 millones de estadounidenses. Greco actualmente forma parte de las juntas de Tapestry, Inc., Sabra Dipping Company y la American Heart Association. Expresó su entusiasmo por el compromiso de Centene de ayudar a los miembros a vivir vidas más saludables.

Centene (NYSE: CNC)은 Thomas R. Greco를 이사회에 임명하였으며, 임기는 2024년 8월 9일부터 시작됩니다. 이로써 이사회는 11명의 구성원으로 확대되며, Greco의 임기는 2025년 정기총회까지 이어집니다. Greco는 40년 이상의 공공 기업 리더십 경험을 가진 베테랑 경영자로, 최근 2016년부터 2023년까지 Advance Auto Parts의 사장 겸 CEO로 재직했습니다. 그 이전에는 PepsiCo에서 30년 이상 근무하며, 2011년에는 Frito-Lay North America의 CEO로 임명되었습니다.

Centene의 CEO Sarah M. London은 Greco의 소비자 마케팅 전문성이 2,850만 미국인의 건강을 개선하는 데 중요한 역할을 할 것이라고 강조했습니다. Greco는 현재 Tapestry, Inc., Sabra Dipping Company, 그리고 American Heart Association의 이사로 활동하고 있습니다. 그는 Centene의 건강한 삶을 살도록 돕겠다는 의지에 대해 열정을 표했습니다.

Centene (NYSE: CNC) a nommé Thomas R. Greco à son Conseil d'Administration, à compter du 9 août 2024. Cela porte le conseil à 11 membres, le mandat de Greco se poursuivant jusqu'à l'assemblée annuelle de 2025. Greco, un dirigeant chevronné avec plus de 40 ans d'expérience dans la direction d'entreprises publiques, a récemment été Président et CEO d'Advance Auto Parts de 2016 à 2023. Avant cela, il a passé trois décennies chez PepsiCo, devenant finalement CEO de Frito-Lay North America en 2011.

La CEO de Centene, Sarah M. London, a souligné l'expertise de Greco en marketing des consommateurs comme étant précieuse pour transformer la santé de 28,5 millions d'Américains. Greco est actuellement membre des conseils d'administration de Tapestry, Inc., Sabra Dipping Company et de l'American Heart Association. Il a exprimé son enthousiasme pour l'engagement de Centene à aider les membres à mener une vie plus saine.

Centene (NYSE: CNC) hat Thomas R. Greco in seinen Vorstand berufen, wirksam ab dem 9. August 2024. Damit wird der Vorstand auf 11 Mitglieder erweitert, und Grecos Amtszeit läuft bis zur Hauptversammlung 2025. Greco ist ein erfahrener Geschäftsführer mit über 40 Jahren in der Führung von börsennotierten Unternehmen und war zuletzt von 2016 bis 2023 Präsident und CEO von Advance Auto Parts. Zuvor verbrachte er drei Jahrzehnte bei PepsiCo, wo er 2011 schließlich CEO von Frito-Lay North America wurde.

Die CEO von Centene, Sarah M. London, hob Grecos Fachwissen im Verbrauchermarketing hervor, das als wertvoll für die Gesundheitsförderung von 28,5 Millionen Amerikanern angesehen wird. Greco ist derzeit Mitglied der Vorstände von Tapestry, Inc., Sabra Dipping Company und der American Heart Association. Er äußerte seine Begeisterung für das Engagement von Centene, den Mitgliedern zu einem gesünderen Leben zu verhelfen.

Positive
  • Appointment of Thomas R. Greco expands the Board of Directors to 11 members
  • Greco brings over 40 years of public company leadership experience
  • Addition of consumer marketing expertise to support Centene's mission
  • Greco's experience in implementing growth strategies and fostering talent development
Negative
  • None.

ST. LOUIS, Aug. 15, 2024 /PRNewswire/ -- Centene Corporation (NYSE: CNC) ("the Company") announced today that it has appointed Thomas R. Greco to the Centene Board of Directors, effective Aug. 9, 2024. Mr. Greco's term will run through the Company's 2025 annual meeting of stockholders. The appointment of Mr. Greco expands Centene's Board of Directors to 11 members.

Mr. Greco is a seasoned operator and executive who brings more than four decades of public company leadership and expertise to Centene. Over the course of his career, he has implemented growth strategies and fostered talent development and diversity for consumer-focused companies. He most recently served as President and Chief Executive Officer (CEO) of Advance Auto Parts, Inc., a Raleigh-based automotive parts retailer, from 2016 to 2023. Prior to his tenure at Advance Auto Parts, Mr. Greco spent three decades in roles of increasing responsibility at PepsiCo before becoming CEO of Frito-Lay North America in 2011.

"Tom's leadership and expertise, particularly in the area of consumer marketing, will be a valuable addition to the Centene Board as we work to transform the health of 28.5 million Americans," said Centene CEO Sarah M. London. "We are pleased to welcome him to the Board of Directors and look forward to his contributions in support of our members and our mission."

Mr. Greco currently serves on the boards of Tapestry, Inc., a publicly traded, multinational fashion company, the Sabra Dipping Company LLC, a joint venture between PepsiCo and the Strauss Group, and the American Heart Association. A longtime advocate for cardiovascular health, Mr. Greco has been actively involved in several initiatives aimed at enhancing the nutritional profile of consumer products throughout his career.  

"Tom brings a unique combination of energy, leadership experience and consumer focus to apply to the healthcare industry," said Chairman of the Board Frederick H. Eppinger.  

"I'm passionate about Centene's commitment to help its members live healthier lives," said Mr. Greco. "It is an honor to join the Board of Directors and apply my skills to help advance the Company's mission."

About Centene Corporation
Centene Corporation, a Fortune 500 company, is a leading healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to more than 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace and the TRICARE program. The Company also contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Centene focuses on long-term growth and value creation as well as the development of its people, systems and capabilities so that it can better serve its members, providers, local communities and government partners.     

Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, http://investors.centene.com/.  

Forward-Looking Statements
All statements, other than statements of current or historical fact, contained in this press release are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "seek," "target," "goal," "may," "will," "would," "could," "should," "can," "continue" and other similar words or expressions (and the negative thereof). Centene Corporation and its subsidiaries (Centene, the Company, our or we) intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about expected contract start dates and terms, our future operating or financial performance, market opportunity, competition, expected activities in connection with completed and future acquisitions and dispositions, our investments and the adequacy of our available cash resources. These forward-looking statements reflect our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, business strategies, operating environments, future developments and other factors we believe appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions. All forward-looking statements included in this press release are based on information available to us on the date hereof. Except as may be otherwise required by law, we undertake no obligation to update or revise the forward-looking statements included in this press release, whether as a result of new information, future events, or otherwise, after the date hereof. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables and events including, but not limited to: our ability to design and price products that are competitive and/or actuarially sound including but not limited to any impacts resulting from Medicaid redeterminations; our ability to maintain or achieve improvement in the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that can impact revenue and future growth; our ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical utilization rates; competition, including for providers, broker distribution networks, contract reprocurements and organic growth; our ability to adequately anticipate demand and provide for operational resources to maintain service level requirements; our ability to manage our information systems effectively; disruption, unexpected costs, or similar risks from business transactions, including acquisitions, divestitures, and changes in our relationships with third parties; impairments to real estate, investments, goodwill, and intangible assets; changes in senior management, loss of one or more key personnel or an inability to attract, hire, integrate and retain skilled personnel; membership and revenue declines or unexpected trends; rate cuts or other payment reductions or delays by governmental payors and other risks and uncertainties affecting our government businesses; changes in healthcare practices, new technologies, and advances in medicine; our ability to effectively and ethically use artificial intelligence and machine learning in compliance with applicable laws; increased healthcare costs; inflation and interest rates; the effect of social, economic, and political conditions and geopolitical events, including as a result of changes in U.S. presidential administrations or Congress; changes in market conditions; changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively referred to as the ACA) and any regulations enacted thereunder; uncertainty concerning government shutdowns, debt ceilings or funding; tax matters; disasters, climate-related incidents, acts of war or aggression or major epidemics; changes in expected contract start dates; changes in provider, broker, vendor, state, federal and other contracts and delays in the timing of regulatory approval of contracts, including due to protests; the expiration, suspension, or termination of our contracts with federal or state governments (including, but not limited to, Medicaid, Medicare or other customers); the difficulty of predicting the timing or outcome of legal or regulatory audits, investigations, proceedings or matters, including, but not limited to, our ability to resolve claims and/or allegations made by states with regard to past practices on acceptable terms, or at all, or whether additional claims, reviews or investigations will be brought by states, the federal government or shareholder litigants, or government investigations; challenges to our contract awards; cyber-attacks or other data security incidents; or our failure to comply with applicable privacy, data or security laws and regulations;  the exertion of management's time and our resources, and other expenses incurred and business changes required in connection with complying with the terms of our contracts and the undertakings in connection with any regulatory, governmental, or third party consents or approvals for acquisitions or dispositions; any changes in expected closing dates, estimated purchase price, or accretion for acquisitions or dispositions; losses in our investment portfolio; restrictions and limitations in connection with our indebtedness; a downgrade of our corporate family rating, issuer rating or credit rating of our indebtedness; the availability of debt and equity financing on terms that are favorable to us and risks and uncertainties discussed in the reports that Centene has filed with the Securities and Exchange Commission (SEC). This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect our business operations, financial condition, and results of operations, in our filings with the SEC, including our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Due to these important factors and risks, we cannot give assurances with respect to our future performance, including without limitation our ability to maintain adequate premium levels or our ability to control our future medical and selling, general and administrative costs.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/centene-announces-the-election-of-thomas-greco-to-board-of-directors-302223896.html

SOURCE CENTENE CORPORATION

FAQ

Who is Thomas R. Greco and when was he appointed to Centene's Board of Directors?

Thomas R. Greco is a seasoned executive with over 40 years of public company leadership experience. He was appointed to Centene 's (NYSE: CNC) Board of Directors effective August 9, 2024.

What is Thomas R. Greco's background and previous experience?

Thomas R. Greco most recently served as President and CEO of Advance Auto Parts from 2016 to 2023. Before that, he spent three decades at PepsiCo, eventually becoming CEO of Frito-Lay North America in 2011.

How long will Thomas R. Greco's term on Centene's Board of Directors last?

Thomas R. Greco's term on Centene's Board of Directors will run through the company's 2025 annual meeting of stockholders.

What specific expertise does Thomas R. Greco bring to Centene's Board?

Thomas R. Greco brings expertise in consumer marketing, implementing growth strategies, and fostering talent development and diversity. His experience is expected to be valuable in transforming the health of Centene's 28.5 million members.

Centene Corporation

NYSE:CNC

CNC Rankings

CNC Latest News

CNC Stock Data

30.17B
504.87M
0.27%
103.47%
1.59%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States of America
ST LOUIS